Coherus Biosciences (CHRS) AI Stock Analysis

• Market Cap: $268.33M
• Dividend Yield: N/A
• Average Volume (3M): 2.51M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: -72.54%
• EPS Growth: -19972.15%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 120,871,010
• 10 Day Avg. Volume: 5,262,590
• 30 Day Avg. Volume: 2,509,855
• PEG Ratio: -0.05
• Price to Book (P/B): -1.20
• Price to Sales (P/S): 0.59
• P/FCF Ratio: -7.73
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 2.27
• Enterprise Value/Gross Profit: 4.76
• Enterprise Value/Ebitda: -1.11
• 1Y Price Target: $7.00
• Price Target Upside: 215.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $2.00 ▼(-9.91% Downside)

The score is held down primarily by weak financial performance (revenue contraction, negative operating metrics, and ongoing cash burn). Offsetting factors include supportive technical momentum and a positive earnings-call narrative around LOQTORZI growth, expense control, and liquidity, with incremental upside from the Janssen collaboration.

Positive Factors

Strategic Collaboration with Janssen

A collaboration with Janssen to run a Phase 1b combination trial reduces single-company trial risk, validates Coherus’ immuno-oncology approach, and preserves commercial rights. This expands strategic combo options and could accelerate clinical development without ceding commercialization upside.

LOQTORZI Commercial Traction

Sustained double-digit QoQ and high YoY growth for LOQTORZI demonstrates improving commercial adoption and execution. Management’s mid-term peak-sales target and salesforce expansion imply scalable revenue potential and provide a measurable pathway to convert clinical success into durable product revenues.

Improved Liquidity and Expense Discipline

A stronger cash position combined with lower SG&A and reduced near-term liabilities materially extends runway and reduces financing pressure. Improved liquidity and lower burn support continued clinical development and commercialization investments, increasing the likelihood of executing mid-term strategic milestones.

Negative Factors

Sharp Revenue Contraction

A ~41% TTM revenue decline indicates material loss of scale and market traction historically. Persisting top-line contraction undermines internal funding capacity for R&D and commercialization, forcing tradeoffs or external financing that could slow program timelines or limit strategic investments.

Persistent Negative Cash Flow

Sustained negative operating and free cash flows reflect weak cash generation from core operations. This ongoing cash burn increases dependence on capital markets, elevates dilution risk, and constrains the company’s ability to self-fund trials and commercialization, making execution contingent on external financing.

Divestiture Reduced Revenue Diversification

The sale of UDENYCA and related biosimilar franchises removes a prior recurring revenue base and narrows the company’s commercial portfolio. Pivoting toward a concentrated oncology portfolio increases reliance on a smaller number of clinical programs and raises revenue volatility if clinical or commercial milestones slip.

Coherus Biosciences Business Overview & Revenue Model

Company Description

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

How the Company Makes Money

Coherus Biosciences generates revenue primarily through the sales of its biosimilar products, which are designed to compete with existing biologic therapies in the market. The company's key revenue streams include the commercialization of its approved biosimilars, which are sold directly to healthcare providers and pharmacies. Additionally, Coherus may engage in partnerships or licensing agreements with other biopharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. These strategic partnerships are crucial for expanding its product portfolio and accelerating market access. Furthermore, Coherus may benefit from cost savings associated with the development of biosimilars compared to original biologics, allowing for competitive pricing and improved profit margins.

Coherus Biosciences Financial Statement Overview

Summary

Financial fundamentals remain weak: sharp TTM revenue decline (-41.47%), pressured profitability with negative EBIT/EBITDA margins, and persistently negative operating/free cash flow. The balance sheet shows some recent improvement (positive equity and reduced leverage), but historical instability and negative ROE keep the score low.

Income Statement

Coherus Biosciences has experienced significant revenue declines in the TTM period, with a negative revenue growth rate of -41.47%. The gross profit margin has decreased from previous years, indicating pressure on profitability. Despite a positive net profit margin in the TTM period, historical data shows consistent net losses, highlighting volatility in earnings. The negative EBIT and EBITDA margins further underscore operational challenges.

Balance Sheet

The company's balance sheet shows improvement in the TTM period with a positive stockholders' equity, reducing the debt-to-equity ratio significantly. However, historical data reveals high leverage and negative equity in prior years, indicating financial instability. The return on equity remains negative, reflecting ongoing profitability challenges.

Cash Flow

Coherus Biosciences has faced consistent negative operating and free cash flows, with a declining trend in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to earnings. Despite a positive free cash flow to net income ratio, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	83.57M	266.96M	257.24M	211.04M	326.55M	475.82M
Gross Profit	39.94M	149.41M	98.25M	140.96M	268.96M	438.16M
EBITDA	-171.31M	60.94M	-193.94M	-255.58M	-260.69M	161.84M
Net Income	154.97M	28.51M	-237.89M	-291.75M	-287.10M	132.24M
Balance Sheet
Total Assets	516.52M	448.53M	629.60M	480.85M	679.33M	841.65M
Cash, Cash Equivalents and Short-Term Investments	191.66M	125.99M	117.75M	191.68M	417.19M	541.16M
Total Debt	40.69M	269.90M	480.84M	480.42M	419.02M	417.10M
Total Liabilities	428.75M	580.52M	823.03M	618.26M	581.61M	560.67M
Stockholders Equity	87.77M	-131.99M	-193.43M	-137.42M	97.73M	280.97M
Cash Flow
Free Cash Flow	-90.19M	-20.44M	-175.17M	-243.16M	-38.72M	146.91M
Operating Cash Flow	-90.19M	-20.44M	-174.88M	-241.12M	-37.43M	154.15M
Investing Cash Flow	377.38M	230.32M	144.64M	-166.85M	-138.41M	-14.40M
Financing Cash Flow	-281.56M	-186.97M	69.60M	54.33M	51.88M	223.95M

Coherus Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRS, the sentiment is Positive. The current price of 2.22 is above the 20-day moving average (MA) of 1.89, above the 50-day MA of 1.55, and above the 200-day MA of 1.24, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 63.44 is Neutral, neither overbought nor oversold. The STOCH value of 56.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHRS.

Coherus Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	59 Neutral	$233.22M	41.87	12.64%	―	35.42%	―
SLS	56 Neutral	$544.13M	-12.30	-84.33%	―	―	59.04%
CHRS	52 Neutral	$268.33M	-1.32	―	―	-72.54%	-19972.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MCRB	50 Neutral	$123.30M	22.07	15.95%	―	448.44%	―
IPHA	49 Neutral	$167.92M	-2.90	-271.32%	―	-75.77%	-31.24%

Coherus Biosciences Corporate Events

Coherus Signs Clinical Supply Deal With Janssen Oncology

On February 4, 2026, Coherus Oncology, Inc. announced a clinical supply agreement with Janssen Research & Development, LLC to evaluate tagmokitug (CHS-114), its investigational anti-CCR8 cytolytic monoclonal antibody, in combination with Janssen’s T-cell engaging bispecific antibody pasritamig in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer. Under the agreement, Janssen will supply pasritamig while Coherus will sponsor the trial, and both companies will retain full commercial rights to their respective compounds, underscoring a collaborative but non-exclusive approach that could broaden future combination therapy options if the study proves successful.

The most recent analyst rating on (CHRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Coherus Biosciences Updates ATM Equity Offering Program

On January 23, 2026, Coherus Oncology, Inc. filed a prospectus supplement tied to its existing sales agreement with TD Securities (USA) LLC (TD Cowen), updating its plan to periodically issue and sell up to $64.88 million of its common stock. The filing enables the company to raise additional equity capital over time through at-the-market offerings, which may support its ongoing oncology programs and strengthen its financial flexibility, with the legal validity of the stock issuance confirmed by an opinion from Latham & Watkins LLP incorporated into the company’s registration statement.

The most recent analyst rating on (CHRS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Coherus Biosciences Divests UDENYCA Business

On April 11, 2025, Coherus Biosciences sold its UDENYCA business, marking a significant divestiture of its biosimilar businesses, which included the UDENYCA, YUSIMRY, and CIMERLI franchises. This strategic shift led to the reclassification of these businesses as discontinued operations in their financial reports, reflecting a focus on their innovative oncology pipeline and the expansion of LOQTORZI sales.

The most recent analyst rating on (CHRS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.